Evidence map›Paper›PMID 38805544›Full record

ArticlePLoS genetics2024

miR-34a is a tumor suppressor in zebrafish and its expression levels impact metabolism, hematopoiesis and DNA damage.

Sergey V Prykhozhij, Kevin Ban, Zane L Brown, Kim Kobar, Gabriel Wajnberg, Charlotte Fuller, Simi Chacko, Jacynthe Lacroix, Nicolas Crapoulet, Craig Midgen and 3 more

Abstract read
In one paragraph

Article in PLoS genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sergey V PrykhozhijChildren's Hospital of Eastern Ontario (CHEO) Research Institute and University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-2801-6122
Kevin BanChildren's Hospital of Eastern Ontario (CHEO) Research Institute and University of Ottawa, Ottawa, Ontario, Canada.
Zane L BrownDalhousie University Medical School, Halifax, Nova Scotia, Canada.
Kim KobarChildren's Hospital of Eastern Ontario (CHEO) Research Institute and University of Ottawa, Ottawa, Ontario, Canada.
Gabriel WajnbergAtlantic Cancer Research Institute, Pavillon Hôtel-Dieu, 35 Providence Street, Moncton, NB, Canada.
Charlotte FullerHHS McMaster University Medical Centre, Division of Medical Microbiology, Hamilton, Ontario, Canada.
Simi ChackoAtlantic Cancer Research Institute, Pavillon Hôtel-Dieu, Moncton, New Brunswick, Canada.
Jacynthe LacroixAtlantic Cancer Research Institute, Pavillon Hôtel-Dieu, Moncton, New Brunswick, Canada.
Nicolas CrapouletAtlantic Cancer Research Institute, Pavillon Hôtel-Dieu, Moncton, New Brunswick, Canada.
Craig MidgenDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Adam ShlienGenetics and Genome Biology Program, The Hospital for Sick Children, PGCRL, Toronto, Ontario, Canada.
David MalkinGenetics and Genome Biology Program, The Hospital for Sick Children, PGCRL, Toronto, Ontario, Canada.
Jason N BermanChildren's Hospital of Eastern Ontario (CHEO) Research Institute and University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-4053-6067

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Li-Fraumeni syndrome is caused by inherited TP53 tumor suppressor gene mutations. MicroRNA miR-34a is a p53 target and modifier gene. Interestingly, miR-34 triple-null mice exhibit normal p53 responses and no overt cancer development, but the lack of miR-34 promotes tumorigenesis in cancer-susceptible backgrounds. miR-34 genes are highly conserved and syntenic between zebrafish and humans. Zebrafish miR-34a and miR-34b/c have similar expression timing in development, but miR-34a is more abundant. DNA damage by camptothecin led to p53-dependent induction of miR-34 genes, while miR-34a mutants were adult-viable and had normal DNA damage-induced apoptosis. Nevertheless, miR-34a-/- compound mutants with a gain-of-function tp53R217H/ R217H or tp53-/- mutants were more cancer-prone than tp53 mutants alone, confirming the tumor-suppressive function of miR-34a. Through transcriptomic comparisons at 28 hours post-fertilization (hpf), we characterized DNA damage-induced transcription, and at 8, 28 and 72 hpf we determined potential miR-34a-regulated genes. At 72 hpf, loss of miR-34a enhanced erythrocyte levels and up-regulated myb-positive hematopoietic stem cells. Overexpression of miR-34a suppressed its reporter mRNA, but not p53 target induction, and sensitized injected embryos to camptothecin but not to γ-irradiation.

Indexed as

DNA DamageHematopoiesisMicroRNAsTumor Suppressor Protein p53ZebrafishZebrafish ProteinsAnimalsApoptosisCamptothecinGene Expression Regulation, DevelopmentalGenes, Tumor SuppressorHumansLi-Fraumeni SyndromeMiceCamptothecinMicroRNAsMIRN34 microRNA, zebrafishtp53 protein, zebrafishTumor Suppressor Protein p53Zebrafish Proteins

Identifiers

PMID38805544
PMCPMC11166285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.